Subsequent analysis of a separate cohort of NRF2-genotyped oral cavity tumors further confirmed that targeted proteomics can identify NRF2 active tumors and quantify immune checkpoint proteins and cancer drivers (Fig. 7). The gene discussed is NFE2L2; the disease is cancer.